Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.
Carlo MümmlerPontus MertschMichaela BarnikelFrank HaubnerUlf SchönermarckUlrich GrabmaierHendrik Schulze-KoopsJuergen BehrNikolaus KneidingerKatrin MilgerPublished in: Journal of asthma and allergy (2024)
In this real-life cohort of patients with severe asthma and EGPA, benralizumab initiation during remission maintenance reduced respiratory exacerbations and daily OCS dose. Benralizumab initiation during remission induction was associated with a high rate of clinical EGPA remission.